Supportive care is not the only option in prostate cancer patients resistant to hormone therapy: the argument for

Eur Urol. 1996:29 Suppl 2:40-4. doi: 10.1159/000473838.

Abstract

In multivariable analyses conducted by several groups, a post-therapy decline in prostate specific antigen was the most significant factor associated with survival of patients with relapsed prostate cancer. Contemporary combination regimens result in consistent declines in prostate-specific antigen in up to 40% of cases, along with objective tumour regression, and the improvement in cancer-related symptoms. It is, therefore, apparent that prostate cancers are not as resistant to treatment as previously believed.

Publication types

  • Review

MeSH terms

  • Analysis of Variance
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / pharmacology
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Neoplasms / radiotherapy
  • Bone Neoplasms / secondary
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Cytoskeleton / drug effects
  • Drug Resistance, Neoplasm
  • Humans
  • Male
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / mortality
  • Neoplasm Recurrence, Local / radiotherapy
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / radiotherapy
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Prostate-Specific Antigen